US20220347175A1 - Pyridazinone derivative - Google Patents

Pyridazinone derivative Download PDF

Info

Publication number
US20220347175A1
US20220347175A1 US17/260,831 US201917260831A US2022347175A1 US 20220347175 A1 US20220347175 A1 US 20220347175A1 US 201917260831 A US201917260831 A US 201917260831A US 2022347175 A1 US2022347175 A1 US 2022347175A1
Authority
US
United States
Prior art keywords
optionally substituted
group
same
substituents selected
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/260,831
Other languages
English (en)
Inventor
Tomoaki Nishida
Hiro UEMACHI
Masato Iwata
Hajime Shibata
Takuya NISHIMAKI
Saori KIYOSHIGE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Assigned to SUMITOMO DAINIPPON PHARMA CO., LTD. reassignment SUMITOMO DAINIPPON PHARMA CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIYOSHIGE, Saori, NISHIDA, TOMOAKI, IWATA, MASATO, NISHIMAKI, Takuya, SHIBATA, HAJIME, UEMACHI, Hiro
Assigned to Sumitomo Pharma Co., Ltd. reassignment Sumitomo Pharma Co., Ltd. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SUMITOMO DAINIPPON PHARMA CO., LTD.
Publication of US20220347175A1 publication Critical patent/US20220347175A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention is directed to a pyridazinone derivative or a pharmaceutically acceptable salt thereof that is useful as a medicament for treating and/or preventing diseases involving sodium channel (especially Nav1.1) and various central nervous system diseases, and a medicament comprising them as an active ingredient.
  • a pyridazinone derivative or a pharmaceutically acceptable salt thereof that is useful as a medicament for treating and/or preventing diseases involving sodium channel (especially Nav1.1) and various central nervous system diseases, and a medicament comprising them as an active ingredient.
  • Nav1.1 is one of voltage-gated sodium channels (VGSC), and expressed in, for example, palvalbmin-positive GABA neurons (PV-GABA neurons). It is known that Nav1.1 is important for the function of neuronal firing in the neurons.
  • VGSC voltage-gated sodium channels
  • PV-GABA neurons palvalbmin-positive GABA neurons
  • Non Patent Literatures 1 and 2 Non Patent Literatures 1 and 2.
  • Dravet syndrome develops in infancy under 1 year old, and it is a serious epileptic encephalopathy in children which causes, for example, various epileptic seizures such as febrile seizures and status epilepticus.
  • valproic acid has been used as in pharmacotherapy of Dravet syndrome, but it is less effective for epileptic seizures.
  • clobazam and stiripentol have been used, but they are less effective for epileptic seizures.
  • Stiripentol is only available in combination therapy with valproic acid or clobazam, which limits the number of patients who receive the drug.
  • a medicament that activates Nav1.1 functions is expected to ameliorate diseases such as schizophrenia, ASD, ADHD, and epilepsy, as well as their associated pathological conditions such as cognitive dysfunction and epileptic seizures, and to treat a wide variety of central nervous system diseases.
  • Non Patent Literature 3 N,N′-(1,3-Phenylene)bis(2-methylbenzamide)
  • Non Patent Literature 4 N,N′-(1,3-Phenylene)bis(2-methylbenzamide) (Non Patent Literature 3) and PF-05661014 (Non Patent Literature 4) are known as exemplary compounds that regulate Nav1.1 functions, but these compounds are different from compounds of the present invention in terms of their chemical structures.
  • Nav1.5 which is another subtype of voltage-dependent sodium channels, is predominantly expressed in heart, and it is known that Nav1.5 contributes to the formation of PR interval, QRS width, and QT interval in electrocardiogram, and involves the electrical conduction between atria and ventricles and the contraction and relaxation of ventricular myocardium. It is also known that antiarrhythmic agents which have inhibitory effect of Nav1.5 prolong the PR interval and QRS width in electrocardiogram. Thus, it is believed that activation of Nav1.5 may affect the PR interval, QRS width, and QT interval in electrocardiogram, the electrical conduction between atria and ventricles, and the contraction and relaxation of ventricular myocardium.
  • One of the problems to be solved by the present invention is to provide a pyridazinone derivative and/or a pharmaceutically acceptable salt thereof that is useful as a medicament for treating and/or preventing diseases involving Nav1.1 and various central nervous system diseases, and a medicament comprising them as an active ingredient.
  • the present inventors have extensively studied to find that a compound of the following formula (1) or a pharmaceutically acceptable salt thereof (hereinafter, referred to as “the present compound”) has a potent activation effect of Nav1.1, and that it can be a medicament that is effective for treating and/or preventing diseases involving Nav1.1 and various central nervous system diseases, and thus, they have accomplished the present invention.
  • amino (1-4) amino, wherein the amino may be optionally substituted with 1 to 2 the same or different substituents selected from the group consisting of:
  • R 1 and R 2 are each independently
  • R 1 and R 2 may be combined together with the carbon atoms to which they attach to form
  • (3-1) a 5- to 7-membered saturated or partially-unsaturated carbocycle, wherein the carbocycle may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of:
  • X 1a , X 1b , X 1c , X 5 , X 6 , X 7 , and X 8 are each independently N or CR 3 ;
  • X 2 , X 3 , and X 4 are each independently CR 3 , O, S, N, or NR 4 ;
  • a 1 and A 2 are each independently N or C;
  • X 1a , X 1b , X 1c , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X8, A 1 , and A 2 are selected such that a ring containing them forms a 9- or 10-membered bicyclic aromatic heterocycle;
  • R x and R y may be combined together with the nitrogen atom to which they attach to form 4- to 7-membered saturated heterocyclyl;
  • R 5 , R 6 , and R 7 are each independently
  • R 5 , R 6 , and R 7 is cyano, 5- or 6-membered heteroaryl (wherein the heteroaryl may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of halogen atom, cyano, and C 1-6 alkyl), 4- to 7-membered saturated or partially-unsaturated heterocyclyl (wherein the heterocyclyl may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of halogen atom, hydroxy, C 1-6 alkyl, and C 1-6 alkoxy), or —C(O)NR x R y (wherein R x and R y are each independently hydrogen atom, C 1-6 alkyl, or saturated or partially-unsaturated C 3-7 carbocyclyl; or alternatively, R x and R y may be combined together with the nitrogen atom to which they attach to form 4- to 7-membered saturated heterocyclyl); or
  • R 5 and R 6 may be combined together with the carbon atom to which they attach to form a 5- to 7-membered saturated or partially-unsaturated carbocycle or heterocycle (wherein the carbocycle and heterocycle may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of halogen atom, oxo, C 1-6 alkyl, C 1-6 alkoxy, and C 2-7 alkoxycarbonyl),
  • a group of formula (2c) may further be optionally substituted with a fluorine atom at a substitutable carbon atom of the ring,
  • R 8 , R 9 , and R 10 are each independently
  • R 8 and R 9 may be combined together with the carbon atoms to which they attach to form a 5- to 7-membered saturated or partially-unsaturated carbocycle or heterocycle, wherein the carbocycle and heterocycle may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of halogen atom and C 1-6 alky,
  • R 8 and R 9 in formula (2d) are not hydrogen atoms at the same time, and the group of formula (2e) may further be optionally substituted with a fluorine atom at a substitutable carbon atom of the ring,
  • R 8 , R 9 , and R 10 are the same as those defined in the above (4-3);
  • n 0, 1, or 2;
  • X 9 is CH 2 or O
  • group of formula (2h) may further be optionally substituted with a fluorine atom at a substitutable carbon atom of the ring,
  • X 10 , X 11 , X 12 , and X 13 are each independently N or CR 11 ;
  • X 10 , X 11 , X 12 , and X 13 are selected such that a 6-membered ring comprising them forms an aromatic heterocycle;
  • X 14 is CR 15 , CHR 15 , NR 16 , or O;
  • a bond comprising a broken line in formula (2j) denotes a double bond
  • a bond comprising a broken line in formula (2j) denotes a single bond
  • X 15 is NR 17 or O
  • each R 11 may be the same or different;
  • R 12 , R 13 , and R 14 are each independently
  • R 12 and R 14 may be combined together with the carbon atoms to which they attach to form a bridged structure
  • k 0, 1, or 2;
  • j 1 , j 2 , j 3 , and j 4 are each independently 0 or 1,
  • k 1 and k 2 are each independently 0 or 1;
  • C 1-6 alkyl optionally substituted with 1 to 3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, saturated or partially-unsaturated C 3-7 carbocyclyl, and C 1-6 alkoxy,
  • C 1-6 alkoxy optionally substituted with 1 to 3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C 1-6 alkoxy, or
  • R 1 and R 2 may be combined together with the carbon atoms to which they attach to form a 5- to 7-membered saturated or partially-unsaturated carbocycle.
  • R 5 and R 6 are each independently
  • R 5 and R 6 is cyano, 5- or 6-membered heteroaryl (wherein the heteroaryl may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of halogen atom, cyano, and C 1-6 alkyl), 4- to 7-membered saturated or partially-unsaturated heterocyclyl (wherein the heterocyclyl may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of halogen atom, hydroxy, C 1-6 alkyl, and C 1-6 alkoxy), or —C(O)NR x R y (wherein R x and R y are each independently hydrogen atom, C 1-6 alkyl, or saturated or partially-unsaturated C 3-7 carbocyclyl; or alternatively, R x and R y may be combined together with the nitrogen atom to which they attach to form 4- to 7-membered saturated heterocyclyl); or
  • R 5 and R 6 may be combined together with the carbon atoms to which they attach to form a 5- to 7-membered saturated or partially-unsaturated carbocycle or heterocycle (wherein the carbocycle and heterocycle may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of halogen atom, oxo, C 1-6 alkyl, C 1-6 alkoxy, and C 2-7 alkoxycarbonyl),
  • group of formula (2c′) may further be optionally substituted with a fluorine atom at a substitutable carbon atom of the ring,
  • R 8 , R 9 , and R 10 are each independently
  • R 8 and R 9 may be combined together with the carbon atoms to which they attach to form a 5- to 7-membered saturated or partially-unsaturated carbocycle or heterocycle, wherein the carbocycle and heterocycle may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of halogen atom and C 1-6 alkyl;
  • R 8 and R 9 of formula (2d) are not hydrogen atoms at the same time, and a group of formula (2e) may further be optionally substituted with a fluorine atom at a substitutable carbon atom of the ring, or
  • R 8 , R 9 , and R 10 are the same as those defined in the above (4) of the present clause.
  • R 8 and R 9 are the same as those defined in the above [3].
  • X 16 is N, C, or CH
  • a bond comprising a broken line denotes a single or double bond
  • n 0, 1, 2, or 3;
  • R a and R b are each independently
  • R a and R b may be combined together with the carbon atom(s) to which they attach to form a 3- to 6-membered saturated carbocycle, wherein the carbocycle may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of:
  • M 1′ is a group of any one of the following formulae (38)-(52):
  • R 1′ and R 2′ are each independently
  • R 3 wherein R 3 , where R 3 s are each independent when existing plurally, is
  • R 3 is hydrogen atom, halogen atom, cyano, C 1-6 alkyl, C 1-6 alkoxy, or amino optionally substituted with 1 to 2 the same or different C 1-6 alkyl.
  • R 3 is hydrogen atom, halogen atom, cyano, C 1-6 alkyl, C 1-6 alkoxy, or amino optionally substituted with 1 to 2 the same or different C 1-6 alkyl.
  • the present compound can have a significant effect on the activation of Nav1.1. Furthermore, in one embodiment, the present compound can have a selective activity to Nav1.1, compared with the activity to different subtypes of voltage-dependent sodium channels such as Nav1.5. Thus, it is expected that the present compound is useful as a medicament for treating and/or preventing diseases involving Nav1.1 and various central nervous system diseases.
  • C 1-6 alkyl is synonymous with alkyl having 1 to 6 carbon atoms.
  • halogen atom examples include fluorine atom, chlorine atom, bromine atom, and iodine atom.
  • C 1-6 alkyl means a straight- or branched-chain saturated hydrocarbon group having 1 to 6 carbon atoms. It is preferably “C 1-4 alkyl”.
  • Examples of the term “C 1-6 alkyl” include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, and 2-ethylbutyl.
  • C 2-7 alkylcarbonyl means a carbonyl group substituted with the above “C 1-6 alkyl”. For example, it is preferably “C 2-4 alkylcarbonyl”. Examples of the term “C 2-7 alkylcarbonyl” include methylcarbonyl, ethylcarbonyl, normal-propylcarbonyl, and isopropylcarbonyl.
  • C 2-6 alkenyl means a straight- or branched-chain unsaturated hydrocarbon group having 1 to 3 carbon-carbon double bonds and 2 to 6 carbon atoms. It is preferably “C 2-4 alkenyl”. Examples of the term “C 2-6 alkenyl” include ethenyl, propenyl, butenyl, pentenyl, and hexenyl.
  • saturated or partially-unsaturated C 3-7 carbocyclyl means a 3- to 7-membered monocyclic or polycyclic saturated or partially-unsaturated hydrocarbon group. It is preferably “saturated or partially-unsaturated C 5-7 carbocyclyl”. Examples of the term “saturated or partially-unsaturated C 3-7 carbocyclyl” include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, and cyclohexenyl.
  • saturated or partially-unsaturated C 4-12 carbocyclyl means a 4- to 12-membered monocyclic or polycyclic saturated or partially-unsaturated hydrocarbon group. It is preferably “saturated or partially-unsaturated C 4-6 carbocyclyl”. Examples of the term “saturated or partially-unsaturated C 4-12 carbocyclyl” include cyclooctyl, cyclodecyl, and cyclododecyl, besides those listed as examples of the above “saturated or partially-unsaturated C 3-7 carbocyclyl”.
  • saturated or partially-unsaturated C 4-12 carbocyclyl includes saturated or partially-unsaturated bicyclic groups and saturated or partially-unsaturated spiro groups. Examples include groups of the following formulae:
  • 5- or 6-membered saturated or partially-unsaturated carbocyclyl means a 5- or 6-membered monocyclic saturated or partially-unsaturated hydrocarbon group.
  • Examples of the term “5- or 6-membered saturated or partially-unsaturated carbocyclyl” include cyclopentyl, cyclohexyl, cyclopentenyl, and cyclohexenyl.
  • 5- to 7-membered saturated or partially-unsaturated carbocycle means a monocyclic or bicyclic saturated or partially-unsaturated hydrocarbon group having 5 to 7 carbon atoms, and includes structures having partially-unsaturated bond(s), structures having bridged structure(s), and structures forming Spiro ring(s).
  • Examples of the term “5- to 7-membered saturated or partially-unsaturated carbocycle” include cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cycloheptene, cyclohexadiene, and cycloheptadiene.
  • 3- to 6-membered saturated carbocycle means a saturated hydrocarbon ring having 3 to 6 carbon atoms, and includes structures forming spiro ring(s).
  • Examples of the term “3- to 6-membered saturated carbocycle” include cyclopropane, cyclobutane, cyclopentane, and cyclohexane.
  • C 1-6 alkyl part of the term “C 1-6 alkoxy” is synonymous with the above “C 1-6 alkyl”. This term is preferably “C 1-4 alkoxy”. Examples of the term “C 1-6 alkoxy” include, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert-butoxy.
  • C 2-7 alkoxycarbonyl means a carbonyl group substituted with the above “C 1-6 alkoxy”. For example, it is preferably “C 2-5 alkoxycarbonyl”.
  • Examples of the term “C 2-7 alkoxycarbonyl” include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, and tert-butoxycarbonyl.
  • 5- or 6-membered heteroaryl means a 5- or 6-membered aromatic group which comprises one or more (for example, 1 to 4) the same or different heteroatoms selected from nitrogen atom, sulfur atom, and oxygen atom, and which may be optionally substituted with oxo.
  • Examples of the term “5- or 6-membered heteroaryl” include groups of the following formulae:
  • the term “5- to 10-membered heteroaryl” includes, for example, a 5- to 10-membered monocyclic or 9- or 10-membered bicyclic aromatic heterocyclyl group.
  • the “5- to 10-membered heteroaryl” group comprises one or more (for example, 1 to 4) the same or different heteroatoms selected from nitrogen atom, sulfur atom, and oxygen atom, and may be optionally substituted with oxo.
  • the bicyclic heteroaryl group also includes fused structures of the above monocyclic heteroaryl group with an aromatic ring (such as benzene and pyridine) or non-aromatic ring (such as cyclohexane and piperidine). Examples of the term “5- to 10-membered heteroaryl” include groups of the following formulae:
  • a bond across a ring means that a “group” having the bond is attached at a substitutable position of the ring to a group.
  • 4- to 7-membered saturated or partially-unsaturated heterocyclyl includes, for example, a 4- to 7-membered monocyclic or polycyclic saturated or partially-unsaturated heterocyclyl group comprising 1 to 2 the same or different atoms selected from nitrogen atom, oxygen atom, and sulfur atom. It is preferably “5- to 7-membered saturated or partially-unsaturated heterocyclyl”.
  • Examples of the term “5- to 7-membered saturated or partially-unsaturated heterocyclyl” include pyranyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuryl, dihydropyrrolyl, dihydrofuranyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, dioxanyl, azepanyl, morpholinyl, and thiomorpholinyl.
  • Examples of the term “4- to 7-membered saturated or partially-unsaturated heterocyclyl” include azetidinyl and oxetanyl, besides those listed as examples of the above “5- to 7-membered saturated or partially-unsaturated heterocyclyl”.
  • examples of the term “4- to 7-membered saturated heterocyclyl” include azetidinyl, oxetanyl, tetrahydropyranyl, tetrahydrofuryl, pyrrolidinyl, imidazolidinyl, piperazinyl, dioxanyl, azepanyl, morpholinyl, and thiomorpholinyl.
  • Each group may be attached to a group via any of carbon atom(s) and nitrogen atom(s) that constitute a ring.
  • 4- to 12-membered saturated or partially-unsaturated heterocyclyl includes, for example, a 4- to 12-membered monocyclic or polycyclic saturated or partially-unsaturated heterocyclyl group comprising 1 to 3 the same or different atoms selected from nitrogen atom, oxygen atom, and sulfur atom. It is preferably a 4- to 10-membered saturated or partially-unsaturated heterocyclyl group. Examples of the group include azocanyl, 1,4-oxazocanyl, 1,5-oxazocanyl, 1,4-diazocanyl, 1,5-diazocanyl, besides those listed as examples of the above “4- to 7-membered saturated or partially-unsaturated heterocyclyl”. Each group may be attached to a group via any of carbon atom(s) and nitrogen atom(s) that constitute a ring.
  • 4- to 7-membered saturated or partially-unsaturated heterocyclyl or “4- to 12-membered saturated or partially-unsaturated heterocyclyl” includes a saturated or partially-unsaturated bicyclic group and a saturated or partially-unsaturated spiro group.
  • nitrogen-containing saturated ring includes a saturated heterocycle comprising one or more nitrogen atoms as ring components.
  • nitrogen-containing saturated ring examples include azetidine, pyrrolidine, and piperidine.
  • 9- or 10-membered bicyclic aromatic heterocycle means a bicyclic aromatic heterocycle which consists of 9 or 10 atoms and comprises 1 to 3 the same or different heteroatoms selected from the group consisting of oxygen atom, nitrogen atom, and sulfur atom, and which may be optionally substituted with oxo.
  • the oxygen atom and sulfur atom of carbonyl, sulfinyl, sulfonyl, and thiocarbonyl which compose the bicyclic aromatic heterocycle do not count as ring members (i.e., the ring size) of the 9- or 10-membered ring nor as heteroatom(s) which compose the ring.
  • 9- or 10-membered bicyclic aromatic heterocycle examples include quinoline, isoquinoline, naphthyridine, quinazoline, quinoxaline, benzofuran, benzothiophene, indole, benzooxazole, benzoisooxazole, benzoimidazole, benzooxadiazole, benzothiadiazole, indolizine, benzofuran, indazole, pyrazolopyridine, imidazopyridine, triazolopyridine, imidazopyrimidine, imidazopyridazine, thiazolopyridine, pyrazolopyrimidine, triazolopyridazine, and furopyridine.
  • 3- to 6-membered saturated heterocycle means a monocyclic or bicyclic saturated heterocycle which consists of 3 to 6 atoms and comprises 1 or 2 the same or different heteroatoms selected from the group consisting of oxygen atom, nitrogen atom, and sulfur atom.
  • the saturated heterocycle includes structures forming spiro ring(s).
  • the saturated heterocycle may be optionally substituted with oxo, and may comprise 1 or 2 carbonyl, thiocarbonyl, sulfinyl, or sulfonyl groups.
  • the oxygen atom and sulfur atom of carbonyl, thiocarbonyl, sulfinyl, and sulfonyl do not count as ring members (i.e., the ring size) of the 3- to 6-membered ring nor as heteroatom(s) which compose the ring.
  • the “3- to 6-membered saturated heterocycle” includes “5- or 6-membered saturated heterocycle”. Examples of the “5- or 6-membered saturated heterocycle” include, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydrofuran, and tetrahydropyran.
  • Examples of the “3- to 6-membered saturated heterocycle” include aziridine and azetidine, besides those listed as examples of the above “5- or 6-membered saturated heterocycle”.
  • Examples of the “6-membered saturated heterocycle” include piperidine, morpholine, and tetrahydropyran.
  • Examples of a pyridazinone ring comprising a 5- to 7-membered saturated or partially-unsaturated carbocycle, wherein the carbocycle is formed by combination of R 1 and R 2 together with the carbon atoms to which they attach, include rings of the following formulae:
  • Examples of a pyridazinone ring comprising a 5- to 7-membered saturated or partially-unsaturated heterocycle, wherein the heterocycle is formed by combination of R 1 and R 2 together with the carbon atoms to which they attach, include rings of the following formulae:
  • Examples of the group of formula (2c) comprising a 5- to 7-membered saturated or partially-unsaturated carbocycle or heterocycle, wherein the carbocycle and heterocycle are formed by combination of R 5 and R 6 together with the carbon atoms to which they attach, include groups of the following formulae:
  • Examples of the group of formula (3) comprising a 3- to 6-membered saturated carbocycle or 3- to 6-membered saturated heterocycle, wherein the carbocycle and heterocycle are formed by combination of R a and R b together with the carbon atom(s) to which they attach, include groups of the following formulae:
  • Examples of the group of formula (2a) or (2b) comprising a 9- or 10-membered bicyclic aromatic heterocycle include groups of the following formulae:
  • R 1 , R 2 , M 1 , and M 2 are shown below, but the technical scope of the present invention shall not be limited to the scope of the following exemplary embodiments. Preferred embodiments shown below may be optionally combined with each other as long as they are not contradict.
  • R 1 and R 2 preferably include, each independently,
  • C 1-6 alkyl optionally substituted with 1 to 3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, saturated or partially-unsaturated C 3-7 carbocyclyl, and C 1-6 alkoxy,
  • C 1-6 alkoxy optionally substituted with 1 to 3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C 1-6 alkoxy, or
  • R 1 and R 2 includes the case when they are combined together with the carbon atoms to which they attach to form a 5- or 7-membered saturated or partially-unsaturated carbocycle.
  • M 1 preferably includes
  • M 1 is further preferably a group of the following formula (3′):
  • X 16 is N, C, or CH; a bond comprising a broken line denotes a single bond or a double bond; m is 0, 1, 2, or 3; R a , R b , R c , and R d are each independently
  • C 1-6 alkoxy optionally substituted with 1 to 3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C 1-6 alkoxy, or
  • R a and R b may be combined together with the carbon atom(s) to which they attach to form
  • M 1 is more preferably a group of formula (3′) wherein X 16 is C or N, m is 1 or 2, R a and R b are each independently hydrogen atom, halogen atom, or C 1-6 alkyl optionally substituted with 1 to 3 the same or different halogen atoms, and R c and R d are hydrogen atoms.
  • M 1 includes groups of the following formulae (3a), (3b), (3c), (3d), (3e), (3f), (3g), (3h), (3i), (3j), (3k), (3m), (3n), (3p), (3q), (3r), (3s), (3t), (3u), (3v), (3w), (3x), (3y), (3z), (3a′), (3b′), (3c′), (3d′), (3e′), and (3f′):
  • M 1 is a group of formula (3a), (3b), (30), (3d), (3e), (3f), (3g), (3h), (3i), (3j), (3k), (3m), (3n), (3w), (3x), (3y), (3z), (3a′), (3b′), (3c′), (3d′), (3e′), or (3f′).
  • M 1 includes a group of the following formula (3′′):
  • R a , R b , R c , and R d are each independently
  • C 1-6 alkoxy optionally substituted with 1 to 3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C 1-6 alkoxy, or
  • R a and R b may be combined together with the carbon atom(s) to which they attach to form
  • M 1 includes a group of the following formula (3′′′):
  • R a , R b , R c , and R d are each independently
  • C 1-6 alkoxy optionally substituted with 1 to 3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C 1-6 alkoxy, or
  • R a and R b may be combined together with the carbon atom(s) to which they attach to form
  • M 2 includes the following groups:
  • X 1a and X 1b are each independently N or CR 3 ;
  • R x and R y may be combined together with the nitrogen atom to which they attach to form 4- to 7-membered saturated heterocyclyl,
  • each R 3 may be the same or different with each other,
  • R 5 is 5-membered heteroaryl optionally substituted with 1 to 2 the same or different substituents selected from the group consisting of halogen atom and C 1-6 alkyl,
  • X 17 is O or CH 2 ;
  • R 19 is hydrogen atom or C 1-6 alkyl, or
  • R 8 , R 9 , and R 10 are each independently
  • X 14 is CR 20 ;
  • R 12 , R 13 , and R 14 are each independently
  • M 2 is a group of the following formula (2a′) or (2b′):
  • X 2 , X 5 , X 6 , X 7 , and X 8 are each independently N, CR 21 , or O, A 1 and A 2 are each independently N or C, wherein X 2 , X 5 , X 6 , X 7 , X 8 , A 1 , and A 2 are selected such that a ring comprising them forms a 9- or 10-membered bicyclic aromatic heterocycle; and R 21 and R 22 are each independently
  • M 2 includes a group of any one of the following formulae (11) to (37):
  • X 1a and X 1b are each independently N or CR 3 ;
  • C 1-6 alkyl optionally substituted with 1 to 3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, saturated or partially-unsaturated C 3-7 carbocyclyl, and C 1-6 alkoxy,
  • R x and R y are each independently hydrogen atom, C 1-6 alkyl, or saturated or partially-unsaturated C 3-7 carbocyclyl; or
  • R x and R y may be combined together with the nitrogen atom to which they attach to form 4- to 7-membered saturated heterocyclyl,
  • each R 3 may be the same or different with each other.
  • M 2 is 4-cyanophenylamino.
  • M 2 includes a group of the following formula (2h′):
  • R 8 , R 9 , and R 10 are each independently
  • C 1-6 alkyl optionally substituted with 1 to 3 the same or different substituents selected from the group consisting of halogen atom; hydroxy; C 1-6 alkoxy optionally substituted with hydroxy or C 1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl optionally substituted with C 1-6 alkyl or C 1-6 alkoxy; 5- or 6-membered heteroaryl optionally substituted with C 1-6 alkyl; and amino, wherein the amino may be optionally substituted with 1 to 2 the same or different substituents selected from the group consisting of C 1-6 alkyl optionally substituted with 1 to 3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C 1-6 alkoxy; saturated or partially-unsaturated C 3-7 carbocyclyl; 4- to 7-membered saturated heterocyclyl optionally substituted with C 1-6 alkoxy; and C 2-7 alkylcarbonyl optionally substituted with 1 to 3
  • R x and R y are each independently hydrogen atom, C 1-6 alkyl, or saturated or partially-unsaturated C 3-7 carbocyclyl; or
  • R x and R y may be combined together with the nitrogen atom to which they attach to form 4- to 7-membered saturated heterocyclyl,
  • R 8 and R 9 may be combined together with the carbon atoms to which they attach to form a 5- to 7-membered saturated or partially-unsaturated carbocycle or heterocycle, wherein the carbocycle and heterocycle may be optionally substituted with 1 to 4 the same or different substituents selected from the group consisting of halogen atom and C 1-6 alkyl.
  • pharmaceutically acceptable salt examples include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate, and nitrate; and organic acid salts such as acetate, propionate, oxalate, succinate, lactate, malate, tartrate, citrate, maleate, fumarate, methanesulfonate, p-toluenesulfonate, benzenesulfonate, and ascorbate.
  • inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate, and nitrate
  • organic acid salts such as acetate, propionate, oxalate, succinate, lactate, malate, tartrate, citrate, maleate, fumarate, methanesulfonate, p-toluenesulfonate, benzenesulfonate, and ascorbate.
  • the present compound encompasses any crystalline forms thereof.
  • a compound of Formula (1) may have at least one asymmetric carbon atom.
  • the present compound encompasses racemates of a compound of Formula (1), as well as optical isomers thereof.
  • a compound of Formula (1) encompasses deuterated compounds in which any one or more 1 H in the compound are replaced with 2 H (D).
  • the present compound may be prepared by the following processes and methods which are combined with common synthetic methods.
  • the functional group when there is a functional group that needs protection, the functional group may be protected as necessary and deprotected after the completion of a reaction or a series of reactions to afford a targeted product, even if the use of the protective group is not specifically indicated.
  • protective groups herein, common protective groups, for example those described in literatures (T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, 3rd Ed., John Wiley and Sons, inc., New York (1999) etc.), may be used. More specifically, protective groups of an amino group include, for example, tert-butoxycarbonyl, benzyloxycarbonyl, p-toluenesulfonyl, o-nitrobenzenesulfonyl, and tetrahydropyranyl.
  • Protective groups of a hydroxy group include, for example, trialkylsilyl, acetyl, benzyl, tetrahydropyranyl, and methoxymethyl.
  • Protective groups of an aldehyde group include, for example, dialkylacetal and cyclic alkylacetal.
  • Protective groups of a carboxyl group include, for example, tert-butyl ester, orthoester, and amide.
  • protective groups can be performed by methods commonly used in organic synthetic chemistry (for example, methods described in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, 3rd Ed., John Wiley and Sons, inc., New York (1999) etc.) or corresponding methods thereof.
  • a compound of Formula (1) is prepared by forming bonds at the positions of a, b, and c:
  • M 1 , M 2 , R 1 , and R 2 are the same as those defined in the above [1].
  • a compound of Formula (1) can be prepared, for example, by the following process:
  • M 1 , M 2 , R 1 , and R 2 are the same as those defined in the above [1];
  • R is C 1-6 alkyl; and
  • LG is a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyl (such as methanesulfonyl and p-toluenesulfonyl)).
  • Step 1-1 Preparation Step of Compound (1)
  • a compound of Formula (1) is prepared by reacting Compound (1-1) with Compound (1-2) in the presence of a base in an appropriate inert solvent.
  • a product synthesized in Preparation Process 4 or 5 described below, or a commercial product may be used.
  • a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.
  • Examples of the base herein include inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium phosphate, potassium phosphate, disodium phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; metal alkoxides such as sodium methoxide and potassium tert-butoxide; and organic bases such as triethylamine, diisopropylethylamine, and pyridine.
  • inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium phosphate, potassium phosphate, disodium phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride
  • metal alkoxides such as sodium methoxide and potassium tert-butoxide
  • organic bases such as triethylamine, diisopropylethylamine, and pyridine.
  • inert solvent examples include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane; halogenated hydrocarbon solvents such as chloroform and dichloromethane; aromatic hydrocarbon solvents such as benzene and toluene; and mixed solvents thereof.
  • aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone
  • ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane
  • halogenated hydrocarbon solvents such as chloroform and dichloromethane
  • the reaction temperature herein is selected from, but not limited to, usually the range of ⁇ 10° C. to 200° C., preferably the range of 0° C. to 40° C.
  • the reaction time herein is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.
  • Step 1-2 Preparation Step of Compound (1-4)
  • Compound (1-4) is prepared by reacting Compound (1-1) with Compound (1-3) according to the method described in Step 1-1.
  • Compound (1-3) a commercial product, or a product synthesized by common methods or corresponding methods thereof may be used.
  • Step 1-3 Preparation Step of Compound (1-5)
  • Compound (1-5) is prepared by hydrolyzing Compound (1-4) by common methods (for example, Protective Groups in Organic Synthesis 3 rd Edition (John Wiley & Sons, Inc.), Comprehensive Organic Transformation, R. C. Laroque et al, VCH publisher Inc., 1989 etc.) or corresponding methods thereof.
  • Step 1-4 Preparation Step of Compound (1)
  • a compound of formula (1) is also prepared by reacting Compound (1-5) with Compound (1-6) in the presence or absence of a base in an appropriate inert solvent using a condensing agent.
  • Compound (1-6) a commercial product, or a product synthesized by common methods or corresponding methods thereof may be used.
  • condensing agent examples include dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIPC), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (WSC), benzotriazol-1-yl-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), diphenylphosphoryl azide (DPPA), N,N-carbonyldiimidazole (CDI), benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), and 7-azabenzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU).
  • DCC dicyclohexylcarbodiimide
  • DIPC diisopropylcarbodiimide
  • WSC 1-
  • additives such as N-hydroxysuccinimide (HOSu), 1-hydroxybenzotriazole (HOBt), and 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (HOOBt) may be added to the reaction.
  • HOSu N-hydroxysuccinimide
  • HBt 1-hydroxybenzotriazole
  • HOOBt 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine
  • Examples of the base herein include organic bases such as triethylamine, diisopropylethylamine, and pyridine; inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium phosphate, potassium phosphate, disodium phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; and metal alkoxides such as sodium methoxide and potassium tert-butoxide.
  • organic bases such as triethylamine, diisopropylethylamine, and pyridine
  • inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium phosphate, potassium phosphate, disodium phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride
  • metal alkoxides such as sodium methoxide and potassium tert-butoxide.
  • inert solvent examples include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane; halogenated hydrocarbon solvents such as chloroform and dichloromethane; aromatic hydrocarbon solvents such as benzene and toluene; and mixed solvents thereof.
  • aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone
  • ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane
  • halogenated hydrocarbon solvents such as chloroform and dichloromethane
  • reaction temperature herein is selected from, but not limited to, usually the range from ⁇ 10° C. to 200° C., preferably the range from 0° C. to 40° C.
  • Reaction time is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.
  • the present step can also be proceeded, for example, by activating a carbonyl group with acid anhydride, mixed acid anhydride, or acid halide, and then reacting with Compound (1-6).
  • a compound of formula (2-4) is prepared, for example, by the following process:
  • R 1 , R 2 , and M 2 are the same as those defined in the above [1];
  • LG is a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyl (such as methanesulfonyl and p-toluenesulfonyl));
  • R 21 and R 22 are alternatively, R 21 and R 22 may be combined together with the nitrogen atom to which they attach to form an optionally-substituted 4- to 12-membered saturated heterocycle.
  • Compound (2-2) is prepared from Compound (2-1) and Compound (1-2) according to the method described in Step 1-1.
  • Compound (2-1) a product synthesized by common methods (for example, those described in Tetrahedron, 2015, 71, 4859, Bioorganic & Medicinal Chemistry Letters, 2015, 25, 1030, etc.) or corresponding methods thereof, or a commercial product may be used.
  • Step 2-2 Preparation Step of Compound (2-4)
  • Compound (2-4) can be prepared by reacting Compound (2-2) with Compound (2-3) in the presence of a base in an appropriate inert solvent.
  • a commercial product, or a product synthesized by common methods or corresponding methods thereof may be used.
  • Examples of the base herein include organic bases such as triethylamine, diisopropylethylamine, and pyridine; inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium hydrogen phosphate, potassium phosphate, disodium hydrogen phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; and metal alkoxides such as sodium methoxide and potassium tert-butoxide.
  • organic bases such as triethylamine, diisopropylethylamine, and pyridine
  • inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium hydrogen phosphate, potassium phosphate, disodium hydrogen phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride
  • metal alkoxides such as sodium methoxide and potassium tert-butoxid
  • inert solvent examples include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; halogenated hydrocarbon solvents such as chloroform and dichloromethane; aromatic hydrocarbon solvents such as benzene and toluene; and mixed solvents thereof.
  • aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone
  • halogenated hydrocarbon solvents such as chloroform and dichloromethane
  • aromatic hydrocarbon solvents such as benzene and toluene
  • mixed solvents thereof examples include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone
  • the reaction temperature herein is selected from, but not limited to, usually the range of 20° C. to 200° C., preferably the range of 50° C. to 170° C.
  • the present step may be conducted under microwave irradiation, if necessary.
  • the reaction time herein is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.
  • R 1 , R 2 , and M 2 are the same as those described in the above [1];
  • LG is a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyl (such as methanesulfonyl and p-toluenesulfonyl));
  • A is boronate, boronate ester, BF 3 K, or BF 3 Na;
  • Q 2 is optionally-substituted 4- to 12-membered partially-unsaturated heterocyclyl or saturated or partially-unsaturated C 4-12 carbocyclyl; and
  • Q 3 is optionally-substituted saturated or partially-unsaturated C 4-12 carbocyclyl, or optionally-substituted 4- to 12-membered saturated heterocyclyl.
  • Step 3-1 Preparation Step of Compound (3-2)
  • Compound (3-2) is prepared by reacting Compound (2-2) with Compound (3-1) in the presence of a palladium catalyst, a phosphine ligand, and a base in an appropriate inert solvent.
  • a palladium catalyst for Compound (3-1), a commercial product, or a product synthesized by common methods or corresponding methods may be used.
  • Examples of the palladium catalyst herein include tetrakis(triphenylphosphine)palladium (0), bis(dibenzylideneacetone)palladium (0), tris(dibenzylideneacetone)dipalladium (0), bis(tri-tert-butylphosphine)palladium (0), palladium (0) acetate, [1,1-bis(diphenylphosphino)ferrocene]palladium (II) dichloride, bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium (II).
  • Phosphine ligands include, for example, o-tolylphosphine, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (S-Phos), 2-(dicyclohexylphosphino)-2′,4′,6′-triisopropylbiphenyl (X-Phos), 1,1′-bis(diphenylphosphino)ferrocene (DPPF), 1,2-bis(diphenylphosphino)ethane (DPPE), 1,3-bis(diphenylphosphino)propane (DPPP), 1,4-bis(diphenylphosphino)butane (DPPB), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XANT-Phos), and bis(2-(dipheny
  • Examples of the base herein include sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, sodium hydroxide, and potassium hydroxide.
  • inert solvent examples include 1,4-dioxane, THF, 1,2-dimethoxyethane, water, and mixed solvents thereof.
  • reaction temperature herein is selected from, but not limited to, usually the range of 50° C. to 200° C., preferably the range of 80° C. to 150° C.
  • the present step can be conducted under microwave irradiation, if necessary. Reaction time is usually 30 minutes to 48 hours.
  • Step 3-2 Preparation Step of Compound (3-3)
  • Compound (3-3) is prepared by catalytic reduction of Compound (3-2) with a metal catalyst in an appropriate inert solvent under hydrogen atmosphere.
  • Examples of the metal catalyst herein include palladium/carbon, palladium hydroxide/carbon, Raney nickel, platinum oxide/carbon, and rhodium/carbon.
  • the amount of a metal catalyst is usually 0.1% to 1000% by weight to Compound (3-2), and preferably 1% to 100% by weight.
  • inert solvent examples include ethers such as tetrahydrofuran; and esters such as ethyl acetate.
  • the hydrogen pressure herein is usually 1 to 100 atm, and preferably 1 to 5 atm.
  • reaction temperature herein is selected from, but not limited to, usually the range of 0° C. to 120° C., preferably the range of 20° C. to 80° C. Reaction time is usually 30 minutes to 72 hours.
  • R 1 and R 2 are the same as those defined in the above [1]; LG 1 and LG 2 are each independently a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyl (such as methanesulfonyl and p-toluenesulfonyl)); R 21 and R 22 are each independently optionally-substituted C 1-6 alkyl, optionally-substituted C 3-10 cycloalkyl, or optionally-substituted C 3-10 cycloalkyl-C 1-4 alkyl; or alternatively, R 21 and R 22 may be combined together with the nitrogen atom to which they attach to form an optionally-substituted 4- to 12-membered saturated heterocycle.
  • LG 1 and LG 2 are each independently a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyl (such as methanesulf
  • Step 4-1 Preparation Step of Compound (4-2)
  • Compound (4-2) is prepared from Compound (4-1) and Compound (2-3) according to the method described in Step 2-2.
  • Compound (4-1) and Compound (2-3) a commercial product, or a product synthesized by common methods (for example, WO 2004/006922, ACS Medicinal Chemistry Letters, 2012, 3, 903. etc.) or corresponding methods thereof may be used.
  • the amount of Compound (2-3) used herein is usually 1.0 equivalent to 1.5 equivalent, and preferably 1.05 equivalent to 1.2 equivalent, to the amount of Compound (4-2).
  • Step 4-2 Preparation Step of Compound (4-3)
  • Compound (4-3) is prepared from Compound (4-2) according to common methods (for example, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 2007, WO 2012/114268, etc.) or corresponding methods thereof.
  • a compound of formula (5-4) is prepared, for example, by the following process:
  • R 1 and R 2 are the same as those defined in the above [1];
  • Q 3 is optionally-substituted saturated or partially-unsaturated C 4-12 carbocyclyl, or optionally-substituted 4- to 12-membered saturated heterocyclyl;
  • G is a metal species such as magnesium and zinc; and
  • X is a halogen atom.
  • Step 5-1 Preparation Step of Compound (5-3)
  • Compound (5-3) is prepared by reacting Compound (5-1) with Organometallic Compound (5-2) such as a Grignard reagent according to common methods (for example, Organic Letters, 2015, 17, 5517, Organic & Biomolecular Chemistry, 2014, 12, 2049, etc.) or corresponding methods thereof.
  • Organometallic Compound (5-2) such as a Grignard reagent
  • As Compound (5-1) and Compound (5-2), commercial products, or products synthesized by common methods for example, Organic Letters, 2008, 10, 4815, Journal of Organic Chemistry, 2015, 80, 12182, etc.
  • Step 5-2 Preparation Step of Compound (5-4)
  • Compound (5-4) is prepared by reacting Compound (5-2) with hydrazine according to common methods (for example, Journal of Medicinal Chemistry, 1993, 36, 4052, WO 2007/020343, etc.) or corresponding methods thereof.
  • the above preparation processes can be optionally combined to provide the present compound which has desired substituents at desired positions.
  • Isolation and purification of intermediates or products in the above preparation processes can be carried out by optional combination of methods which are commonly used in organic synthetic chemistry, such as filtration, extraction, washing, drying, concentration, crystallization, and various types of chromatography. Intermediates can also be subjected to a subsequent reaction without any particular purification.
  • Some material compounds or intermediates in the above preparation processes may exist in a salt form such as hydrochloride according to, for example, reaction conditions, and they can be used as they are or in a free form.
  • a salt form such as hydrochloride according to, for example, reaction conditions
  • materials compounds or intermediates can be converted into a free form by dissolving or suspending them in an appropriate solvent, followed by neutralization with a base such as a sodium bicarbonate solution.
  • Some compounds of Formula (1) or pharmaceutically acceptable salts thereof may have isomers including tautomers such as keto-enol forms, regioisomers, geometric isomers, or optical isomers. All possible isomers including them, and mixtures of such isomers in any ratio, are also encompassed in the present invention.
  • optical isomers can also be separated by common separation processes such as methods using an optically active column or fractional crystallization at an appropriate step of the above preparation processes.
  • An optically active material can be used as a starting material.
  • a salt of a compound of Formula (1) when the compound of Formula (1) is obtained in a salt form, the salt can be obtained by purification of the obtained salt, and when the compound of Formula (1) is obtained in a free form, the salt can be formed by dissolving or suspending the compound of Formula (1) in an appropriate solvent, followed by addition of an acid or base.
  • Compound (1) or a pharmaceutically acceptable salt thereof may exist in a form of hydrate or solvate (e.g., ethanolate) with various types of solvents such as water and ethanol, and such hydrates and solvents are also encompassed in the present invention.
  • the present compound may be useful as a medicament for activating Nav1.1 because it exhibits the activation effect of Nav1.1.
  • the present compound have the activation effect of Nav1.1 and thus, may be useful as a medicament for treating and/or preventing diseases involving Nav1.1, especially diseases involving reduced function of Nav1.1, for example as a medicament for treating and/or preventing central nervous system diseases (for example, febrile seizure; generalized epilepsy with febrile seizure plus; epilepsy (specifically, focal epilepsy, generalized epilepsy); epileptic syndrome (such as Dravet syndrome, intractable childhood epilepsy with generalized tonic-clonic seizure, epilepsy with myoclonic-atonic seizure, West syndrome, Lennox-Gastaut syndrome, infantile spasms, sever infantile multifocal epilepsy, severe myoclonic epilepsy, borderline; and benign familial neonatal-infantile seizure); schizophrenia; autism spectrum disorder; and attention deficit hyperactivity disorder).
  • central nervous system diseases for example, febrile seizure; generalized epilepsy with febrile seizure plus; epi
  • the present compound is expected as a medicament for treating and/or preventing the above epileptic syndrome or epilepsy (especially, intractable epilepsy) wherein symptoms cannot be adequately suppressed with multiple drugs, especially three or more existing antiepileptic agents.
  • One embodiment of the present invention has a selective pharmacological activity especially to Nav1.1, and less to other subtypes of Nav, such as Nav1.5, and thus, the possibility of cardiotoxicity is expected to be reduced to provide high safety.
  • preventing refers to the act of administering the present compound to a healthy person who has not developed a disease, and is intended, for example, to prevent the onset of a disease.
  • treating refers to the act of administering the present compound to a person, i.e., a patient, who has been diagnosed by a doctor as being affected with a disease.
  • the present compound may be administered directly via an appropriate route of administration, or administered in an appropriate dosage form after formulation.
  • route of administration it is preferable to use the most effective route for treatment, and examples of the route of administration include oral; and parenteral administration such as intravenous administration, application, inhalation, and eye drop.
  • the route of administration is preferably oral administration.
  • Examples of the dosage form herein include a tablet, a capsule, a powder, a granule, a liquid, a suspension, an injection, a patch, and a poultice.
  • the dosage form is preferably a tablet.
  • Formulation into a dosage form or a pharmaceutical composition can be carried out according to common methods using pharmaceutically acceptable additives.
  • an excipient As a pharmaceutically acceptable additive, an excipient, a disintegrant, a binder, a fluidizer, a lubricant, a coating, a solubilizer, a solubilizing adjuvant, a thickener, a dispersant, a stabilizing agent, a sweetening agent, a flavor, and the like can be used, depending on a purpose.
  • examples of the pharmaceutically acceptable additive herein include lactose, mannitol, crystalline cellulose, low-substituted hydroxypropylcellulose, corn starch, partially-pregelatinized starch, carmellose calcium, croscarmellose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, propylene glycol, titanium oxide, and talc.
  • the amount and the frequency of administration of these dosage forms or pharmaceutical compositions can be optionally determined depending on the mode of administration, a disease of a patient or symptoms thereof, the age or weight of a patient, and the like.
  • the amount of an active ingredient (herein, also referred to as “therapeutically effective amount”) per day can usually be administered to an adult in several portions in a day, preferably in one to three portions in a day, wherein the amount ranges from about 0.0001 to about 5000 mg, more preferably from about 0.001 to about 1000 mg, further preferably from about 0.1 to about 500 mg, especially preferably from about 1 to about 300 mg.
  • the present compound may be used in combination with another agent (hereinafter, also referred to as an “agent for combination use”) in order to enhance the effect of the present compound and/or reduce side effects.
  • agents include antiepileptic agents, antipsychotic agents, antidepressant agents, mood-stabilizing agents, antianxiety agents, psychostimulant drugs, antiemetic agents, sleep-introducing agents, anticonvulsant agents, antiparkinsonian agents, antischizophrenic agents, and therapeutic agents for ADHD.
  • the present compound can also be combined with agents such as signal enhancing agents of GABA including valproic acid; positive allosteric modulators of GABAA receptors including clobazam; T-type voltage-dependent calcium channel inhibitors including ethosuximide; SV2A ligands including levetiracetam; medicaments of partial seizure including carbamazepine; calcium channel a2 ⁇ (alpha 2 delta) ligands including pregabalin; voltage-dependent potassium channel activators including retigabine; and AMPA receptor antagonist including perampanel.
  • agents such as signal enhancing agents of GABA including valproic acid; positive allosteric modulators of GABAA receptors including clobazam; T-type voltage-dependent calcium channel inhibitors including ethosuximide; SV2A ligands including levetiracetam; medicaments of partial seizure including carbamazepine; calcium channel a2 ⁇ (alpha 2 delta) ligands including pregabalin; voltage-dependent potassium channel activators including
  • the present compound may also be used in combination with multi-acting receptor-targeted antipsychotic agents (MARTA) including clozapine; serotonin-dopamine antagonists (SDA) including risperidon; dopamine receptor partial agonists (DPA) including aripiprazole; selective serotonin reuptake inhibitors (SSRI) including fluvoxamine; serotonin noradrenaline reuptake inhibitors (SNRI) including duloxetine; noradrenergic and specific serotonergic antidepressant agents (NaSSA) including mirtazapine; mood-stabilizing agents including lithium carbonate; serotonin 1A receptor agonists including tandospirone; histamine H1-receptor antagonists including hydroxyzine; central nervous system stimulants including methylphenidate; and selective noradrenaline reuptake inhibitors including atomoxetine.
  • MARTA multi-acting receptor-targeted antipsychotic agents
  • SDA serot
  • the timing to administer the present compound and an agent for combination use is not limited, and they may be administered to a subject of treatment concurrently or with a time lag.
  • the present compound may be formulated as a combination medicament with an agent for combination use.
  • the dose or mixing ratio of such agent can be optionally selected depending on a subject to be administered, a route of administration, a targeted disease, symptoms, and combination thereof, on the basis of the doses in the clinical use.
  • an agent for combination use may be used in 0.01 to 100 parts by weight to 1 part by weight of the present compound.
  • CDCl 3 deuterated chloroform
  • DMSO-d 6 deuterated dimethylsulfoxide
  • Rt retention time min: minute(s)
  • HATU O-(7-aza-1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate
  • THF tetrahydrofuran
  • TFA trifluoroacetic acid
  • Symbols used in NMR are defined as follows: s for singlet, d for doublet, dd for doublet of doublets, t for triplet, td for triplet of doublets, q for quartet, m for multiplet, br for broad singlet or multiplet, and J for coupling constant.
  • HPLC ACQUITY UPLC (registered trademark) SYSTEM
  • HPLC ACQUITY UPLC (registered trademark) SYSTEM
  • Solvents Solution A; 0.06% formic acid/H 2 O, Solution B; 0.06% formic acid/acetonitrile
  • Solvents Solution A; 0.05% TFA/H 2 O, Solution B; acetonitrile
  • Solvents Solution A; 10 mM NH 4 HCO 3 /H 2 O, Solution B; acetonitrile
  • Solvents Solution A; 0.05% formic acid/H 2 O, Solution B; acetonitrile
  • 3,6-Dichloro-4-methylpyridazine (650 mg) was dissolved in acetic acid (6 mL), and the reaction mixture was subjected to microwave irradiation, and stirred at 200° C. for 2 hours. After cooling to room temperature, the following steps were repeated three times: toluene was added thereto, and the mixture was concentrated under reduced pressure. The residue was dissolved in dimethylformamide (3 mL), and methyl bromoacetate (855 mg) and potassium carbonate (1.10 g) were added thereto. The mixture was stirred at room temperature overnight. After the addition of saturated aqueous ammonium chloride, the mixture was extracted with ethyl acetate.
  • Example 3 to 36 According to the method of Example 1 or 2 and common reaction conditions, the compounds of Examples 3 to 36 were obtained by using corresponding material compounds.
  • Example 39 to 49 were obtained by using corresponding material compounds.
  • Example 50 According to the method of Example 50 and common reaction conditions, the compounds of Examples 51 to 99 were obtained by using corresponding material compounds.
  • the compounds of Examples 100 to 135 were obtained by using corresponding material compounds.
  • Example 37 or 50 According to the methods of Example 37 or 50 and common reaction conditions, the compounds of Examples 136 to 159 were obtained by using corresponding material compounds.
  • Example 1 According to the method of Example 1, 2, or 50 and common reaction conditions, the compounds of Examples 160 to 192 were obtained by using corresponding material compounds.
  • Example 239 to 243 According to the method of Example 1, 37, or 50 and common reaction conditions, the compounds of Examples 239 to 243 were obtained by using corresponding material compounds.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US17/260,831 2018-07-19 2019-07-18 Pyridazinone derivative Abandoned US20220347175A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-136152 2018-07-19
JP2018136152 2018-07-19
PCT/JP2019/028256 WO2020017587A1 (ja) 2018-07-19 2019-07-18 ピリダジノン誘導体

Publications (1)

Publication Number Publication Date
US20220347175A1 true US20220347175A1 (en) 2022-11-03

Family

ID=69163916

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/260,831 Abandoned US20220347175A1 (en) 2018-07-19 2019-07-18 Pyridazinone derivative

Country Status (6)

Country Link
US (1) US20220347175A1 (https=)
EP (1) EP3828174A4 (https=)
JP (1) JP7476100B2 (https=)
CN (1) CN112672997A (https=)
CA (1) CA3105681A1 (https=)
WO (1) WO2020017587A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12054486B2 (en) 2021-09-24 2024-08-06 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
WO2025215121A1 (en) * 2024-04-09 2025-10-16 Imperial College Innovations Limited Hedgehog acyltransferase inhibitors

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3877052B1 (en) 2018-11-06 2023-08-16 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
ES2958954T3 (es) 2018-11-06 2024-02-16 Edgewise Therapeutics Inc Compuestos de piridazinona y usos de los mismos
WO2020097258A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
WO2021141041A1 (ja) * 2020-01-07 2021-07-15 大日本住友製薬株式会社 タウオパチーの治療剤
WO2021149767A1 (ja) * 2020-01-22 2021-07-29 大日本住友製薬株式会社 ヘテロ環誘導体
JP2023523418A (ja) * 2020-04-23 2023-06-05 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｌｒｐ３の阻害剤としての三環式化合物
KR20230035049A (ko) * 2020-07-02 2023-03-10 데날리 테라퓨틱스 인크. 화합물, 조성물 및 방법
CN116964052A (zh) * 2021-03-04 2023-10-27 詹森药业有限公司 调节nlrp3的4-氨基-6-氧代-哒嗪衍生物
MX2023010310A (es) * 2021-03-04 2023-09-12 Janssen Pharmaceutica Nv Derivados de 4-alcoxi-6-oxo-piridazina que modulan nlrp3.
CN115650968B (zh) * 2022-12-27 2023-03-21 英矽智能科技(上海)有限公司 作为cdk选择性抑制剂的新型哒嗪酮化合物
GB2640329A (en) * 2024-04-09 2025-10-15 Imperial College Innovations Ltd Hedgehog acyltransferase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210685A1 (en) * 2016-06-03 2017-12-07 An2H Discovery Limited Pyradazinone derivatives and the compositions and methods of treatment regarding the same
WO2018081378A1 (en) * 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
WO2018081377A1 (en) * 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100770327B1 (ko) * 2000-09-18 2007-10-25 에자이 알앤드디 매니지먼트 가부시키가이샤 피리다지논 및 트리아지논 화합물류 및 그들의 의약 용도
GB0216224D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
FR2889847B1 (fr) 2005-08-18 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
EP2145891A1 (en) * 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
US20140073651A1 (en) 2011-02-22 2014-03-13 Actelion Pharmaceuticals Ltd. Benzamide derivatives as p2x7 receptor antagonists
CN102964340B (zh) * 2012-12-12 2015-10-07 中国药科大学 一类治疗阿尔茨海默病的选择性多巴胺d1受体激动剂
EP2968323A4 (en) * 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
EP3419621A4 (en) * 2016-02-26 2019-10-30 The Johns Hopkins University PHARMACOLOGICAL MODULATORS OF NAV1.1 VOLTAGE-CONTROLLED SODIUM CHANNELS ASSOCIATED WITH MECHANICAL PAIN

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210685A1 (en) * 2016-06-03 2017-12-07 An2H Discovery Limited Pyradazinone derivatives and the compositions and methods of treatment regarding the same
WO2018081378A1 (en) * 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
WO2018081377A1 (en) * 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Akhtar et al. Eur J Med Chem. 2016, Nov 10:123:256-281. doi: 10.1016/j.ejmech.2016.07.061. "The therapeutic journey of pyridazinone" (Year: 2016) *
Asif et al. Brazilian Journal of Pharmaceutical Sciences, 2018;54(3):e00040, Studies on new substituted pyridazinones: synthesis and biological evaluation. (Year: 2018) *
CAS Registry # 1282112-34-8, N-(3,5-Dichlorophenyl)-3-(4-methyl-1-piperidinyl)-6-oxo-1(6H)-pyridazineacetamide, entered on April 19,2011, (Year: 2011) *
Giovannoni et al. European Journal of Medicinal Chemistry (2013), 64, 512-528. (Year: 2013) *
Partap et al. Arch. Pharm. Chem. Life Sci. 2017, 350, e1700135, Design, Synthesis, and Pharmacological Screening of Pyridazinone Hybrids as Anticonvulsant Agents. (Year: 2017) *
Singh et al. , J. Heterocyclic Chem., 54, 2935 , 2017, "Synthesis and Biological Evaluation of 2-substituted-6- (morpholinyl/piperidinyl)pyridazin-3(2H)-ones as Potent and Safer Anti- inflammatory and Analgesic Agents" (Year: 2017) *
STN database, CAS Registry # 1282101-76-1, N-(3-Chlorophenyl)-3-(4-methyl-1-piperidinyl)-6-oxo-1(6H)-pyridazineacetamide, entered on April 19,2011 (Year: 2011) *
STN database, CAS Registry # 1282109-79-8, N-[3-(Acetylamino)phenyl]-3-(4-methyl-1-piperidinyl)-6-oxo-1(6H)-pyridazineacetamide, entered on April 19,2011 (Year: 2011) *
STN database, CAS Registry #1282110-75-1, 3-(4-Methyl-1-piperidinyl)-6-oxo-N-(3,4,5-trifluorophenyl)-1(6H)-pyridazineacetamide, entered on April 19, 2011, (Year: 2011) *
STN database, CAS# 2330258-85-8, N-(4-Cyanophenyl)-3-(4-methylphenyl)-6-oxo-1(6H)-pyridazineacetamide, entered on June 12, 2019 (Year: 2019) *
Waszkielewicz et al. Current Medicinal Chemistry, Volume 20, Number 10, 2013, pp. 1241-1285(45), Ion Channels as Drug Targets in Central Nervous System Disorders. (Year: 2013) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12054486B2 (en) 2021-09-24 2024-08-06 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
WO2025215121A1 (en) * 2024-04-09 2025-10-16 Imperial College Innovations Limited Hedgehog acyltransferase inhibitors

Also Published As

Publication number Publication date
CN112672997A (zh) 2021-04-16
EP3828174A1 (en) 2021-06-02
EP3828174A4 (en) 2022-08-17
JP7476100B2 (ja) 2024-04-30
CA3105681A1 (en) 2020-01-23
JPWO2020017587A1 (ja) 2021-08-05
WO2020017587A1 (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
US20220347175A1 (en) Pyridazinone derivative
US6906072B1 (en) Piperazine compound and pharmaceutical composition containing the compound
TW202039435A (zh) 經取代之3-((3-胺基苯基)胺基)哌啶-2,6-二酮化合物、其組合物及使用彼等之治療方法
US11345666B2 (en) Phenyl and pyridinyl substituted imidazoles as modulators of RORγT
US20120058939A9 (en) Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8729264B2 (en) Agent for prevention and/or treatment of skin diseases
CN107141309A (zh) 杂芳基化合物及其使用方法
US20210070750A1 (en) Halo-allylamine ssao/vap-1 inhibitor and use thereof
US10975057B2 (en) 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
JP2022502370A (ja) 置換ピリジニル化合物およびその使用
US20200239419A1 (en) Novel tetrahydronaphthyl urea derivative
KR20190097006A (ko) 5-히드록시트립타민 수용체 7의 신규 조절제 및 이의 사용 방법
US11046679B2 (en) Indoleamine 2,3-dioxygenase inhibitor and application
ES2492694T3 (es) Nuevos compuestos espiroheterocíclicos como antagonistas de mGlu5
US20160318933A1 (en) Fused pyrazole derivative
US20130012496A1 (en) Benzazepine compound
US20230109839A1 (en) Therapeutic agent for tauopathies
US20230002383A1 (en) Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use
WO2021149767A1 (ja) ヘテロ環誘導体
TW202529754A (zh) Tyk2抑制劑及其用途
US11401270B2 (en) Alcoxyamino derivatives for treating pain and pain related conditions
US20250129080A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
HK40053244A (en) Pyridazinone derivative
CN106336387A (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
US20070270436A1 (en) Novel amino- and imino-alkylpiperazines

Legal Events

Date Code Title Description
AS Assignment

Owner name: SUMITOMO DAINIPPON PHARMA CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NISHIDA, TOMOAKI;UEMACHI, HIRO;IWATA, MASATO;AND OTHERS;SIGNING DATES FROM 20201222 TO 20201224;REEL/FRAME:054935/0328

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: SUMITOMO PHARMA CO., LTD., JAPAN

Free format text: CHANGE OF NAME;ASSIGNOR:SUMITOMO DAINIPPON PHARMA CO., LTD.;REEL/FRAME:060161/0046

Effective date: 20220401

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION